Bone Biologics (BBLG) Notes Payables (2013 - 2021)

Bone Biologics (BBLG) has reported Notes Payables for 9 consecutive years, with $12.8 million the latest figure, recorded in Q3 2021.

• In Q3 2021, Notes Payables rose 10.07% year-over-year to $12.8 million; the TTM figure through Sep 2021 stood at $12.8 million (up 10.07% YoY), while the FY2020 annual figure was $10609.0, changed N/A from the prior year.
• Notes Payables improved to $12.8 million in Q3 2021 per BBLG's latest filing, from $12.5 million in the prior quarter.
• Across five years, Notes Payables topped out at $12.8 million in Q3 2021 and bottomed at $102.0 in Q2 2020.
• Historically, Notes Payables has averaged $7.2 million across 5 years, with a median of $9.7 million in 2019.
• Annual changes were most pronounced in 2020 — Notes Payables sank 100.0% — and 2021, when it jumped 12246164.71%.
• Bone Biologics' Notes Payables stood at $2.9 million in 2017, then soared by 211.65% to $9.0 million in 2018, then grew by 24.44% to $11.2 million in 2019, then sank by 99.91% to $10609.0 in 2020, then soared by 120249.67% to $12.8 million in 2021.
• Business Quant data shows BBLG's Notes Payables at $12.8 million in Q3 2021, $12.5 million in Q2 2021, and $11.9 million in Q1 2021.